Partners
Prof. Stéphane DEDIEU
Scientific coordinator
Prof. Stéphane DEDIEU is the co-director of a 40 people research team at UMR CNRS 7369 MEDyC aiming to develop therapeutic targeting of the extracellular matrix. He gained recognized expertise in thrombospondin biology and contributed to engineering the TAX2 peptide. He authored more than 60 international publications in the field. He is co-founder and chair of the Scientific and Clinical Board of Apmonia Therapeutics. He sits on many scientific boards and regularly takes part in national/international scientific expertise. Principal investigator of more than 30 research projects over the last 15 years, including multi-team and multi-disciplinary projects, he is currently leading an INCa project and an industrial maturation program, and is involved as partner’s scientific leader in the Smart Bone Organoid ANR program (CE19, Technology for health).
Dr. Pascal MAURICE
Scientific leader
CNRS Research Director, Dr. Pascal MAURICE is a member of the team « Matrix Aging and Vascular Remodeling » at UMR CNRS 7369 MEDyC, is specialized in the molecular aging of ECM macromolecules and its pathophysiological consequences in metabolic and vascular diseases such as atherosclerosis and thrombosis. Dr. Pascal Maurice has a long-standing experience in the field of hemostasis and thrombosis, platelet function, and related murine models of thrombosis attested by numerous high-ranked publications.
Scientific leader
INSERM Research Director, Dr. Véronique REGNAULT has long-standing experience in the field of coagulation and thrombin-vessel wall interactions and is internationally recognized for its expertise in both basic and clinical aspects of arterial wall structure and function. In the field of acquired thrombophilia, her results brought new insights on an integrated hypercoagulable biological phenotype associated with thrombotic risk and identified the relative contributions of platelet procoagulant activities and of activated protein C resistance to this phenotype. She is currently the leader of the “Vascular stiffness-inflammation-thrombosis” team at UMRS 1116.
Scientific leader
Dr. Albin JEANNE is the President & CSO of Apmonia Therapeutics. He combines strong strategic, technological, and managerial skills with over 10-year experience in translational drug development. Albin JEANNE co-founded Apmonia Therapeutics in 2019 and has raised as of now a total of more than €8 million from VCs and strategic partners in Europe. As a co-inventor of TAX2 patents, he engineered the first ever antagonists being selective for TSP- 1/CD47 interaction, has authored 15 peer-reviewed scientific publications on TSP-1 pathobiology, and won numerous international awards. Albin JEANNE holds a PhD in biochemistry & cell biology and completed the Challenge+ program at HEC international business school.
